stockrow
Friday 6 November 2026
Export TCMD’s income statement to Excel — free account
Tactile Systems Technology, Inc.
TCMD Healthcare Medical Devices
Tactile Systems Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $329.5 million, up 12.5% from fiscal 2024.
- Revenue
- +7.12%
- EPS
- −14.5%
- Free cash flow
- +23.8%
Quarter to September 2026, against a year earlier
26.07
0.30
−1.14%
Follow TCMD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.30 | 27.07 | 29.03 | 34.12 |
+8 more quarters Free account |
P/S ratio |
1.42 | 1.93 | 1.72 | 2.01 | |
P/FCF ratio |
17.48 | 25.32 | 15.08 | 16.47 | |
P/Operating CF |
42.12 | 207.54 | (1,739.00) | 38.35 | |
P/B ratio |
2.22 | 3.02 | 2.71 | 3.03 | |
Price to Tangible BV |
3.50 | 4.84 | 4.33 | 4.46 | |
EV/Sales |
1.22 | 1.75 | 1.52 | 1.78 | |
EV/EBITDA |
10.77 | 14.67 | 13.41 | 16.31 | |
EV/Operating CF |
13.55 | 20.04 | 12.39 | 13.68 | |
EV/FCF |
15.12 | 22.96 | 13.33 | 14.55 | |
Quick Ratio |
2.92 | 3.37 | 3.57 | 3.49 | |
Current Ratio |
3.51 | 4.12 | 4.24 | 4.03 | |
Net Debt/EBITDA |
(7.92) | (9.82) | (858.96) | (4.86) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.30 | 1.27 | 1.24 | 1.15 | |
Operating CF/Net income |
1.67 | 0.42 | 0.19 | 1.63 | |
Capex/Depreciation |
(0.34) | (0.73) | (0.51) | (0.36) | |
Interest Coverage |
479.55 | 359.26 | (54.79) | 1,706.82 | |
Research and Development Expense of Revenue |
2.73% | 2.92% | 3.69% | 2.44% | |
Selling, General and Administrative Expense of Revenue |
62.81% | 64.61% | 74.10% | 57.05% | |
Intangible Assets out of Total Assets |
0.29 | 0.30 | 0.30 | 0.26 | |
Share Based Compensation of Revenue |
2.59% | 2.64% | 2.36% | 2.45% | |
Graham Net Nets |
0.20 | 0.15 | 0.17 | 0.17 | |
Graham Number |
15.38 | 15.63 | 13.98 | 13.53 | |
Earnings Yield |
4.69% | 3.69% | 3.44% | 2.93% | |
Free Cash Flow Yield |
5.72% | 3.95% | 6.63% | 6.07% | |
Revenue per Share |
4.06 | 3.78 | 3.34 | 4.53 | |
Operating CF per Share |
0.53 | 0.14 | (0.01) | 0.76 | |
Capex per Share |
(0.03) | (0.06) | (0.04) | (0.03) | |
Free Cash Flow per Share |
0.50 | 0.09 | (0.05) | 0.73 | |
Cash per Share |
3.98 | 3.74 | 4.00 | 4.34 | |
Shareholders Equity per Share |
10.04 | 9.87 | 9.66 | 9.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.04 | 9.87 | 9.66 | 9.57 | |
Free Cash Flow |
11.38 | 1.94 | (1.17) | 16.72 | |
Working Capital |
119.28 | 119.35 | 116.83 | 124.21 | |
Capital Expenditures |
(0.60) | (1.32) | (0.83) | (0.58) | |
Net Current Asset Value |
102.74 | 101.77 | 98.59 | 110.13 | |
EV/EBIT |
12.96 | 17.48 | 16.14 | 20.01 | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
14.99 | 19.28 | 18.26 | 22.66 | |
| Other line items | |||||
Average Receivables |
43.05 | 38.80 | 37.55 | 44.41 | |
Average Payables |
9.89 | 7.97 | 7.17 | 5.31 | |
Average Inventory |
15.84 | 16.98 | 17.72 | 16.35 | |
Average Assets |
275.24 | 276.36 | 276.18 | 285.93 | |
Average Common Equity |
216.10 | 209.38 | 211.75 | 217.75 |
Columns are period end dates · fundamentals updated 5 Nov 2026